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transcranial direct current stimulation: treatments
for cognitive and neuropsychiatric symptoms in
the neurodegenerative dementias?
Greg J Elder* and John-Paul TaylorAbstract
Introduction: Two methods of non-invasive brain stimulation, transcranial magnetic stimulation (TMS) and
transcranial direct current stimulation (tDCS), have demonstrable positive effects on cognition and can ameliorate
neuropsychiatric symptoms such as depression. Less is known about the efficacy of these approaches in common
neurodegenerative diseases. In this review, we evaluate the effects of TMS and tDCS upon cognitive and
neuropsychiatric symptoms in the major dementias, including Alzheimer’s disease (AD), vascular dementia (VaD),
dementia with Lewy bodies (DLB), Parkinson’s disease with dementia (PDD), and frontotemporal dementia (FTD),
as well as the potential pre-dementia states of Mild Cognitive Impairment (MCI) and Parkinson’s disease (PD).
Methods: PubMed (until 7 February 2014) and PsycINFO (from 1967 to January Week 3 2014) databases were
searched in a semi-systematic manner in order to identify relevant treatment studies. A total of 762 studies were
identified and 32 studies (18 in the dementias and 14 in PD populations) were included.
Results: No studies were identified in patients with PDD, FTD or VaD. Of the dementias, 13 studies were conducted
in patients with AD, one in DLB, and four in MCI. A total of 16 of the 18 studies showed improvements in at least
one cognitive or neuropsychiatric outcome measure. Cognitive or neuropsychiatric improvements were observed in
12 of the 14 studies conducted in patients with PD.
Conclusions: Both TMS and tDCS may have potential as interventions for the treatment of symptoms associated
with dementia and PD. These results are promising; however, available data were limited, particularly within VaD,
PDD and FTD, and major challenges exist in order to maximise the efficacy and clinical utility of both techniques. In
particular, stimulation parameters vary considerably between studies and are likely to subsequently impact upon
treatment efficacy.Introduction
Dementia is associated with significant financial and soci-
etal costs. The worldwide cost of dementia in 2009 was es-
timated to be US$422 billion [1]. By 2050, the number of
new cases is projected to be more than double the inci-
dence in 2000 [2]. Individuals with dementia display a
range of associated cognitive and neuropsychiatric seque-
lae. Whilst a number of medications are used to manage
these symptoms, pharmacological treatments have only a* Correspondence: greg.elder@ncl.ac.uk
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article, unless otherwise stated.limited degree of efficacy and in some cases (for example,
antipsychotics) may be accompanied by significant side ef-
fects. Therefore, there is an urgent need to develop alter-
native treatments.
One area which has garnered considerable clinical and
research interest recently is the use of non-invasive brain
stimulation. In this review, we explore whether two of the
most common of these approaches, transcranial magnetic
stimulation (TMS) and transcranial direct current stimu-
lation (tDCS), might be used to treat symptoms associated
with the most common forms of neurodegenerative dis-
ease, including Alzheimer’s disease (AD), vascular demen-
tia (VaD), dementia with Lewy bodies (DLB), Parkinson’stral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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tia (FTD). Additionally, we consider the application of
TMS and tDCS in people with mild cognitive impairment
(MCI), which is a recognised risk state for the develop-
ment of dementia and, in particular, dementia associated
with AD [3]. Similarly, we also consider the application of
both techniques in individuals with Parkinson’s disease (PD),
as PD is considered to be a significant risk factor for PDD
[4] and cognitive deficits are apparent even in early PD [5].
Methods of non-invasive stimulation
Transcranial magnetic stimulation
TMS modulates cortical plasticity, where a brief (100 μs)
electrical current is delivered through a coiled wire placed
on the scalp, resulting in a time-varying magnetic field
across the skull (1.5 to 2 Tesla), which induces an electric
field and subsequently alters neuronal activity [6,7]. The
dosage is typically determined by the stimulation intensity
and is often calibrated to the person-specific motor-evoked
potential (MEP) threshold [8]. Whilst safe, the most com-
mon side effect of TMS is transient pain (with a prevalence
of approximately 40%), typically dependent on an individ-
ual’s tolerability to the location, intensity or frequency of
stimulation [7]. TMS cannot be used in individuals with
metallic equipment situated near the coil and carries a low
risk (<1% in normal populations) of inducing seizures [7].
Stimulation protocols include ‘single-pulse’ stimulation,
‘paired-pulse’ TMS and repetitive TMS (rTMS); in the lat-
ter, low-frequency (≤1 Hz), high-frequency trains, or vary-
ing bursts of stimulation (for example, theta-burst
stimulation (TBS)) can be delivered [7].
Cortical neurons 1.5 to 3 cm below the scalp may be
activated, depending on the stimulation intensity. In-
creasing the stimulation intensity and frequency in-
creases cortical disruption; however, stimulation trains
modulate cortical excitability, and the subsequent effects
depend on the stimulation parameters. Typically, higher
frequencies (for example, 20 Hz) increase and lower fre-
quencies (approximately 1 Hz) suppress cortical excit-
ability [6,7,9], although low-frequency stimulation may
not always cause inhibitory effects [10]. Continuous TBS
results in inhibitory after-effects, whilst intermittent TBS
results in facilitatory after-effects, at least in the case of
the motor cortex [11]. The duration of after-effects are
affected by the stimulation protocol. Single-pulse and
short rTMS protocols result in after-effects lasting a few
seconds; long or multiple rTMS trains result in after-
effects of several minutes to 1 hour; and TBS protocols
can result in after-effects of up to 8 hours [12,13]. Lon-
ger effect durations can occur with TMS, when repeated
daily, as poststimulation effects can be observed even up
to 1 month later [14].
TMS has been shown to reduce neuropsychiatric symp-
toms and improve cognition. In older people, for example,a double-blind study in adults over 50 years of age with
memory problems showed that rTMS led to improve-
ments in associative memory [15] and an open-label study
showed that rTMS over a 3-week period significantly re-
duced the severity of depressive symptoms in older adults
[16]. These data are supported by meta-analytic results
demonstrating that high-frequency TMS applied to the
left dorsolateral prefrontal cortex (DLPFC) was superior to
sham stimulation in double-blind treatment studies of de-
pression, with effects comparable to pharmacological treat-
ment [17]. Importantly, the therapeutic effects of TMS
may be additive, as repeated sessions over a 6-week period
have been suggested to lead to cumulative improvements
in mood [18]. TMS may also modulate and enhance motor
learning, vision, memory and attention in healthy individ-
uals [13]. Taken together, these results suggest that TMS
might be a potential method of treatment for cognitive and
neuropsychiatric symptoms associated with dementia.
Transcranial direct current stimulation
Another non-invasive treatment method is tDCS, where
a weak electrical current is delivered through two scalp
electrodes by a portable battery-powered stimulator. An
anodal and cathodal electrode, typically between 25 cm2
and 35 cm2 in size, are inserted into holding bags moist-
ened with saline or conductive gel and are placed on the
scalp in accordance with the International 10–20 system
[19]. The current density, calculated on the basis of the
power intensity divided by the area of the electrode, is
used as a marker of dosage and influences the after-
effects [19]. Current densities of 0.05 mA/cm2 are typ-
ical, although they can range from 0.02 mA/cm2 to
0.08 mA/cm2 [19]. It has been speculated that tDCS
modulates spontaneous neuronal activity in a polarity-
specific manner [20], whereby the tDCS current has a
modulatory effect upon cortical excitability by either in-
creasing or decreasing intrinsic neural firing. Specifically,
anodal stimulation typically increases the membrane po-
tential by several millivolts, whereas cathodal stimulation
typically results in an opposite effect, decreasing the
membrane potential [19,21,22]. However, these effects do
not appear to be consistent across studies [19,23]. There
are no reports of serious adverse effects with tDCS; com-
mon side effects include mild tingling, fatigue and light
itching under the electrodes [19].
Relevant normative and clinical studies suggest that
tDCS may be a useful therapeutic tool. For example, it
may have utility in the treatment of depression; in one
study individuals who received active tDCS showed an
improvement in mood compared to placebo stimulation
followed by an open-label phase [24]. Accompanying
short-term improvements in attention and working mem-
ory were also observed [24]. Post-tDCS improvements
have also been shown in young healthy controls in terms
Search terms:
“Alzheimer*”, “dementia”,
“frontotemporal dementia”, “vascular 
dementia”, “Parkinson’s disease”,
“Parkinson’s disease with dementia”,
“Lewy body*”, “cognitive impairment”,
AND “magnetic stimulation” or “current
stimulation”
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performance [26]. Similar to TMS, the benefits of tDCS
may be additive. In one study, participants who had received
active tDCS over 5 consecutive days displayed greater per-
formance on a motor skill task compared to sham stimu-
lation, with these effects persisting at a 3-month follow-up
time point [27].PubMED
(Until 7 February 2014)
PsycINFO
(From 1967 until January Week 
3 2014)
502 articles for potential
inclusion
260 articles for potential
inclusion
Articles screened 
(Removal of non-treatment 
studies, review articles and
non-English articles)
Articles screened 
(Removal of non-treatment 
studies, review articles and
non-English articles)
45 articles for inclusion 37 articles for inclusion
82 articles for inclusion
Removal of duplicate 
articles
32 articles:
Dementias: 18 articlesMethods
Search methods and inclusion and exclusion criteria
In order to evaluate the clinical utility of either TMS or
tDCS in the symptomatic treatment of AD, VaD, DLB, PD,
PDD, FTD or MCI, only treatment studies were included.
PubMed (until 7 February 2014) and PsycINFO (from 1967
to January week 3, 2014) databases were searched using the
following terms: “Alzheimer*” , “dementia” , “frontotemporal
dementia” , “vascular dementia” , “Parkinson*” , “Parkinson’s
disease with dementia” , “Lewy body*” , “cognitive impair-
ment” AND “magnetic stimulation” or “current stimulation”.
As this review was focussed on the treatment of cognitive
and neuropsychiatric symptoms, studies which used
either TMS or tDCS to specifically ameliorate other
symptoms alone (for example, motor symptoms) were
excluded.
This search strategy (Figure 1) resulted in 762 po-
tential articles for inclusion. The examination of rele-
vant review papers did not result in any additional
articles for inclusion. Article titles and abstracts were
examined and non-treatment studies, review, non-
English and duplicate articles were removed, leaving a
total of 32 studies (18 within the dementias and 14 in
PD populations).(13 TMS, 5 tDCS)
Parkinson’s disease: 14 articles 
(12 TMS, 2 tDCS)
Figure 1 Study search strategy and selection process.Results
The majority of the studies in the dementias examined
cognitive outcome measures [28-42] whilst several exam-
ined neuropsychiatric symptoms [43-45]. A total of 13
studies targeted AD patients [28-33,37-42], 4 studies in-
cluded MCI patients [34-36,43] and 1 study involved DLB
patients [44]. No studies reported the therapeutic use of
TMS or tDCS in individuals with VaD, PDD, or FTD. A
total of 14 studies examined cognitive and neuropsychi-
atric outcome measures in individuals with PD [46-59].
Within dementia, improvements were shown on at least
1 measure in 16 of the 18 studies, and TMS was the
most common method of stimulation (13 studies). In
the dementias, improvements were shown in cognitive
(Additional file 1: Table S1) and neuropsychiatric symp-
tom domains (Additional file 2: Table S2). The variety
of symptoms and outcomes reported precluded any for-
mal statistical meta-analysis. In PD, cognitive and
neuropsychiatric improvements were observed in 12 of
the 14 studies (Additional file 3: Table S3), and TMSwas the most common modality, being used in a total of
12 studies.
Discussion
Treatments targeting cognition in Alzheimer’s disease
In AD, there was a general trend for improvements across
a wide range of cognitive outcome measures following
treatment with TMS and tDCS [28-42]. Typical sites
of stimulation included the DLPFC [28-31,37,42], tem-
poral regions [38], temporoparietal regions [41] or a com-
bination of multiple regions [32,33,39]. However, sample
sizes were often small (including single-case studies
[36,37,43]), and the majority were open-label in design.
Nevertheless, these studies will help inform future work
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the utility and effectiveness of non-invasive stimulation,
were apparent:
1. The frequency of stimulation is an important factor
in the field of neurostimulation in general and is
therefore very likely to influence any potential
cognitive improvements that might occur in
dementia. In one study, Mini Mental State
Examination (MMSE), Instrumental Activities of
Daily Living Scale (IADL) and Geriatric Depression
Scale (GDS) scores were shown to improve in
patients with AD following high-frequency
rTMS, but not following low-frequency or sham
stimulation [28].
2. The benefits of TMS or tDCS may also be highly
task-specific, as, for example, AD patients showed
improvements within an action-naming task compared
to sham TMS, but not within an object-naming task
[29]. Boggio and colleagues showed that active tDCS
resulted in improvements in visual recognition
memory, but not in selective attention or working
memory performance [39]. Similarly, in another
study, improved visual recognition performance
was shown compared to sham tDCS; however,
cognitive (MMSE & Alzheimer's Disease Assessment
Scale - cognitive subscale (ADAS-Cog)) and visual
attention measures were unaffected [38].
3. There was some evidence to suggest that the beneficial
effects of TMS could be sustained in AD, with one
study reporting that auditory sentence comprehension
improvements were observed two weeks after
stimulation, although this benefit was not sustained
across various other cognitive measures, including
MMSE scores [31]. Preliminary findings in another
study in AD with tDCS have shown that 4 weeks of
active stimulation led to MMSE, action-naming task
and noun-naming task improvements at a 12-week
follow-up time point, although the stimulation
parameters were not reported in this study, making
replication challenging [40].
4. Dementia severity may affect the TMS response,
as whilst poststimulation action-naming and
object-naming improvements have been reported in
patients with moderate to severe AD compared to
sham stimulation, only action-naming improvements
have been observed in patients with mild AD [30].
In contrast, in another study with a crossover design
in patients with MCI, the effects of TMS upon a range
of neuropsychological tests, including executive
function, attention, working memory, psychomotor
speed and visuomotor coordination, were negligible
[35], thus making it difficult to conclude whether
the level of cognitive impairment (or lackthereof ) is important for TMS response or
nonresponse.
5. The location of stimulation is likely to have a major
influence upon the therapeutic efficacy of TMS or
tDCS. For example, low-frequency rTMS delivered
to the right DLPFC resulted in improvements in
non-verbal recognition task performance in MCI
patients, compared to left DLPFC or sham stimulation
[34]. For tDCS, current polarity is likely to be an
important factor for treatment efficacy; one study
reported that whilst word recognition improvements
in an AD cohort were shown after bilateral anodal
stimulation, no improvements were observed
following sham stimulation and performance
worsened following cathodal stimulation, with
visual attention unaffected [41].
6. Other studies have combined TMS with cognitive
training. This has a neurobiological basis, as rTMS
has been suggested to influence learning in a
neuroplastic fashion, with consequent changes to
synaptic function [12]. In patients with AD,
Bentwich and colleagues trialled cognitive tasks,
whose operation was ‘localised’ to specific brain
regions (Broca’s area, Wernicke’s area, left and right
DLPFC and left and right parietal somatosensory
association cortex), including syntax, grammar,
action-naming and spatial memory tasks, with the
difficulty adjusted on the basis of patient performance
[32]. These brain regions were targeted using
rTMS whilst the cognitive tasks were performed.
Poststimulation improvements were shown in the
primary outcome measure (ADAS-Cog), but not
on the secondary outcome measure (MMSE).
However, that study was hampered by the small
sample size (n = 8), the lack of a placebo condition
and the inability to separate the effects of TMS from
the effects of cognitive training. In a similar study,
Rabey et al. assessed the effects of combined rTMS and
cognitive training on ADAS-Cog scores (primary
measure) in patients with AD [33], but included a
placebo rTMS and cognitive training group. Compared
to the placebo condition, positive results were
observed at two follow-up time points (6 weeks
and approximately 4 months). However, similar to
the study conducted by Bentwich and colleagues, it is
unclear whether rTMS or cognitive training alone re-
sulted in the beneficial effects, or whether the effects
were combined.
Overall, it is evident that there is a great deal of meth-
odological heterogeneity in the use of non-invasive brain
stimulation in these studies. In order to advance the
use of both techniques, the replication of studies is
necessary.
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mild cognitive impairment
We found no studies in which researchers examined the
cognitive benefits of either TMS or tDCS in VaD, DLB,
PDD or FTD. Four studies have examined the effects
of TMS upon individuals with MCI, although, we
found no studies using tDCS in this group. One
cross-over study showed that TMS resulted in only
negligible effects upon a range of neuropsychological
tests in patients with MCI (n = 7) [35] and a further
study showed that TMS resulted in an improvement
in non-verbal recognition memory [34]. A single-
case study suggested that TMS resulted in improve-
ments to a range of measures, including associative
memory [36].
Treatments targeting cognition and neuropsychiatric
symptoms in Parkinson’s disease
The majority of studies conducted in individuals with
PD employed TMS (12 of the 14 studies; Additional
file 3: Table S3) and improvements were observed in 12
of the studies. As in the dementias, a great deal of meth-
odological heterogeneity was apparent; however, the
overall results suggest that TMS might benefit depres-
sive symptoms in patients with PD and that the positive
effects may persist at follow-up time periods of up to
8 weeks in some cases [47,48,50-52,54,56,57]. Neverthe-
less, the ability to directly translate these positive find-
ings to dementia patient groups might be limited, as the
investigators in these studies did not knowingly include,
or report findings on, PD patients with cognitive impair-
ment. As was the case in studies conducted in other popu-
lations, an obvious limitation is the open-label nature of
several studies [51,52,56]. In all cases, adequately powered,
placebo-controlled studies are necessary to confirm these
promising results.
Several trials incorporated treatment and placebo
combinations of anti-depressant medication and TMS,
generally showing comparable improvements in mood
to those observed using anti-depressant medication with
sham TMS [48,50,53]. However, due to the lack of a
combined active TMS and anti-depressant group, it has
not been possible to examine whether or not these
effects are additive.
The effects of TMS upon cognition are less clear, as
improvements in a range of secondary outcome mea-
sures have been reported in individuals with PD, includ-
ing neuropsychological tests [48,55,57] and MMSE
scores [50], although these findings are not consistent
across all studies [58]. However, the effects of TMS
might be location-specific, since in one crossover study
Tower of London task improvements were observed
after rTMS was delivered to the right DLPFC, and not
the left DLPFC [59].Only two studies to date have employed tDCS within
PD [46,49]; one of which observed that 2 mA of anodal
stimulation applied to the prefrontal cortices did not im-
prove depression, quality of life, or measures within a re-
action time task [46]. However, Boggio and colleagues
observed that 2 mA, but not 1 mA, of anodal stimulation
applied to the left DLPFC resulted in improved accuracy
on a working memory task [49], suggesting that the
current density might be an important factor in maximis-
ing the efficacy of techniques. Benninger et al. [46] did
not observe any effects of stimulation upon measures
of depression or quality of life, or within a reaction
time task. However, in this randomised, double-blind,
sham-controlled study the aim was to examine whether
tDCS benefitted motor symptoms, and there were no
differences shown between active and sham stimulation.
It is possible that the lack of studies which have used
tDCS within PD or PDD for cognitive symptoms is due
to the preoccupation of its effect (or absence thereof )
upon motor symptoms [60]; nevertheless, the use of
tDCS in order to examine any non-motor benefits
should be encouraged.
Treatment targeting neuropsychiatric symptoms in
dementia
Very few studies have specifically examined the effects of
TMS or tDCS upon neuropsychiatric symptoms in de-
mentia, either as a primary or a secondary outcome meas-
ure. The limited published data has primarily reported on
TMS and its use as a treatment of depression; for
example, TMS has been reported to reduce depressive
symptoms in suspected or probable DLB patients with
treatment-resistant depression [44]. However, a major
limitation of this particular study was the lack of a placebo
group and the small sample size (n = 6) [44]. Another
small study reported improvements in depressive symp-
toms in AD patients, although this was not a primary out-
come measure [28]. Perhaps the most rigorous study
examining the use of non-invasive stimulation in the treat-
ment of neuropsychiatric symptoms was a double-blind,
sham-controlled study which found that tDCS was not an
effective method in the treatment of apathy within AD,
with no benefit shown upon secondary outcomes includ-
ing depression, cognition or other neuropsychiatric symp-
toms [45].
Whilst there is a substantive evidence base for the use
of TMS in the treatment of psychosis in schizophrenia
[61], we did not find any studies where TMS or tDCS was
used to treat psychosis in dementia. Notably, a single-case
study conducted in an MCI patient reported a reduction
in the frequency of auditory verbal hallucinations follow-
ing TMS, which was accompanied by a reduction in
threatening content during the hallucinations and in asso-
ciated distress [43].
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transcranial direct current stimulation in dementia
Overall, there is a clear dearth of high-quality and
adequately-powered trial data regarding the use of TMS
and tDCS in the treatment of cognitive and neuropsychi-
atric symptoms in dementia, although the findings for
both stimulation modalities are generally suggestive of a
potential therapeutic benefit. The lack of robust data may
reflect the relative novelty of these approaches and their
use in dementia, and also the practical difficulties of per-
forming intervention studies in these patient groups.
Additionally, as is typical for new modalities of treatment,
and due to the partial neurobiological understanding of
how both methods modulate cognitive and neuropsychi-
atric symptoms, a significant number of challenges remain
for the optimisation of the therapeutic benefits:
1. Dementia patients are frequently on a range of
psychotropic medications, and it is well-established
that firstly, a wide array of drugs can interact with
the effects of TMS, and secondly, TMS can itself
affect neurotransmitters and neuromodulators [62].
Thus, psychotropic medication use, in conjunction
with non-invasive stimulation, might potentially lead
to unexpected effects, by either enhancing or
suppressing any treatment benefits arising from
TMS or tDCS. For example, in the case of tDCS,
administration of the N-methyl-D-aspartate
(NMDA) receptor antagonist dextromethorphan has
been shown to suppress the effects of anodal and
cathodal tDCS [63], which may have implications
for the concurrent use of memantine, an NMDA
receptor antagonist which is used as a symptomatic
treatment in dementia [64]. Examples of other
psychotropic drugs which are sometimes prescribed
for dementia and could potentially interact with
tDCS include carbamazepine, citalopram,
amphetamine, levodopa and lorazepam, amongst
others [20,63].
2. From a stimulation perspective, the treatment
response in patients with dementia could also be
affected by changes in brain morphology. Structural
brain lesions can affect the tDCS current flow [20],
and TMS is highly dependent upon the distance
between scalp and cortical surface [65]. Grey matter
atrophy can alter the effect of TMS, as the cortical
current density is dependent upon the degree of
atrophy [66]. This is particularly relevant to
dementia populations, since extensive atrophy,
particularly in AD [67,68], might also affect the
treatment response. There are techniques which can
potentially overcome this difficulty, including, for
example, calibrating the distance of the TMS coil to
each individual patient in accordance with thedegree of atrophy [69]. In the case of tDCS,
computational techniques can potentially model the
current flow within atrophied brains and thereby
assist in the optimisation of electrode montages, or
electrode design, within the dementias [70,71]. It is
also possible that these techniques could ultimately
be used to model the response to stimulation [70] at
an individual patient level; therefore, the clinical
utility of such techniques should be examined.
3. Furthermore, the effects of stimulation, and
specifically the TMS current flow, may also be
affected by other factors, including the distribution
of cerebrospinal fluid (CSF), which has an
amplifying effect due to the increased CSF
conductivity compared to other brain tissue [72].
Therefore, ventricular enlargement, which is a
common feature in neurodegenerative diseases,
could be influential in determining the stimulation
intensity needed to obtain a treatment effect.
4. A further challenge is that treatment studies must
clearly define the specific symptom targeted by TMS
or tDCS, which is likely to depend on the
population. For example, individuals with AD are
likely to present with primarily amnestic deficits
(particularly in the early stages) whereas other
dementias such as DLB or PDD may display various
symptoms including cognitive fluctuations, and
attentional or visuoperceptual dysfunction [73].
Moreover, where a target symptom has been clearly
defined, an appropriate clinical measure for assessing
the treatment response to TMS/tDCS is needed.
This can be particularly difficult for neuropsychiatric
symptoms where scales of individualised symptoms
often lack good reliability and validity and are not
sensitive to the symptom change over time [74].
5. Determining the most appropriate location for TMS
or tDCS will complicate any trial design, although
aetiological models of a particular symptom may aid
the choice of location. For example, such models
have implicated the underactivity of DLPFC in
depression [75], and thus non-invasive stimulation
over this area may be the most appropriate location
for treating depression. Nevertheless, the effects of
TMS and tDCS may not be limited to one particular
area and are likely to modulate activity in other
regions [76,77]. Therefore, models suggesting localised
cortical effects under the TMS coil or tDCS
electrodes are potentially over-simplistic and more
research is needed to understand the overall network
effects of stimulation.
6. Perhaps one of the greatest challenges lies in the
wide range of TMS and tDCS stimulation
parameters which could be (and indeed have been)
applied in dementia populations (Additional file 1:
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further work is needed to determine the optimal
stimulation parameters for treatment. This includes
the current density (in the case of tDCS) and the
stimulation frequency, the number of treatment
sessions and how often they occur, as well as the
duration, and the interval between stimulation
sessions, since these factors are likely to significantly
impact upon stimulation efficacy. In particular,
maximising the after-effects will be particularly
important if non-invasive treatments are to be
clinically viable in dementia populations, and help
minimise the number of treatment sessions needed
to obtain meaningful symptom improvements. For
example, in the case of TMS, the use of TBS
protocols might maximise any after-effects [12,13],
although the utility and safety of this approach in
dementia populations has yet to be elucidated.
Overall, these factors prevent definitive conclusions
being made about the underlying true efficacy of non-
invasive stimulation in the treatment of dementia
symptoms, with possible false negatives arising as a conse-
quence of small sample sizes and suboptimal stimulation.
Conversely, as the majority of reported studies are open-
label or uncontrolled in their design, reports will be in-
evitably biased towards positive outcomes; therefore,
caution needs to be exercised in reaching definitive
conclusions about efficacy. Negative results have been
reported in the use of tDCS [78]. Importantly, in order
to avoid potential positive publication biases, and
advance the clinical utility of both techniques, it is
strongly recommended that researchers fully report all
trial results, including negative findings. This approach
will undoubtedly help to define the most appropriate
stimulation parameters needed to obtain a given cogni-
tive effect.
There are a variety of ways in which the challenges out-
lined above may be overcome. Trials in healthy individ-
uals, or in those with mild disease, may allow finessing of
stimulation parameters and establish the tolerability of
protocols. It should be recognised that there may be a
direct interaction between pathology and the subsequent
treatment response, which may make the response
more or less likely in milder disease [30]. Therefore,
normative studies, in conjunction with either single-
case or small open-label patient studies, would be
helpful in establishing treatment parameters and eluci-
dating the potential efficacy of TMS and tDCS. Positive
outcomes in these studies might then inform larger trials
with double-blind, placebo-controlled designs which can
lend themselves to meta-analytic approaches. Issues with
adequate blinding and the lack of good placebos have be-
deviled therapeutic trials with TMS [79]. In this respect,tDCS may offer an advantage over TMS, as double-blind
placebo designs are much more robust using tDCS
[80]. That said, there are difficulties in conducting
double-blind studies using both tDCS and TMS, although
possible solutions exist (such as increasing the ramping-
up time within tDCS studies) [81].
The efficacy of treatment might also be maximised
through methods of stratification, where patients are
selected on the basis of, for example, neuropsychological
performance, genetics or physiological markers. Various
studies have adopted this approach. Where probable AD
patients were stratified on the basis of MMSE per-
formance, mild patients showed improved post-rTMS
action-naming task performance, whilst moderate-to-
severe patients showed improved action-naming and
object-naming task performance [30]. Similarly, post-rTMS
improvements in depression and cognition have been shown
in mild-to-moderate, but not severe, AD patients [28].
From a genetic perspective, Brunoni and colleagues dem-
onstrated that the 5-HTTLPR serotonin transporter poly-
morphism predicted the treatment response to tDCS
treatment for depression, where long/long homozygotes
displayed a larger improvement compared to short allele
carriers, in a dose–response manner [82]. This is also rele-
vant to TMS, as plasticity has been shown to be affected
by the brain-derived neurotrophic factor (BDNF) Val66-
Met genotype [12]. Obvious polymorphic targets in de-
mentia could include apolipoprotein E (APOE) and
microtubule-associated protein τ (MAPT), given their
known association with AD and α-synuclein related dis-
orders [83]. Specifically in PD, dysexecutive impairments
and activity in frontoparietal executive networks may de-
pend on functional polymorphisms in the dopamine regu-
lating the catechol-O-methyltransferase (COMT) enzyme
[84]. Hypothetically, stratification on the basis of the
COMT allelic expression in these patients and those
with PDD might determine treatment responsivity.
Finally, physiological predictors or biomarkers could be
considered; in an rTMS study, the cerebral blood flow
of patients with treatment-resistant major depressive
disorder was assessed pre-treatment and post-treatment
[85]. Individuals who showed a response to treatment
showed greater baseline levels of resting state blood flow
at the rTMS site compared to individuals who did not
respond to treatment.
Other methodological factors might increase stimula-
tion efficacy. Techniques to aid TMS coil placement may
improve the treatment response, such as stereotactic sys-
tems which can enable specific regions to be targeted on
the basis of an individual patient’s structural magnetic res-
onance imaging (MRI) scan. The use of MRI may there-
fore reduce the number of patients required, optimise
stimulation intensities needed to overcome potential
changes in brain morphology, and increase effect sizes in
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fered by this individually-targeted approach to stimulation
[8]. In the case of tDCS, the size and shape of the elec-
trode may affect the treatment response by altering the
focality of the current [19]. Most tDCS studies use two
rectangular electrodes for stimulation. However, methods
such as high-definition tDCS, where four cathode elec-
trodes are positioned around an anodal electrode, may
allow for better regional targeting [71]. The therapeutic ef-
fects of alternating polarity during repeated stimulation
sessions of tDCS, where, for instance, anodal stimulation
could be applied before cathodal stimulation, are yet to be
explored, but as polarity-dependent effects have been ob-
served within tDCS [19], this approach may be worthy of
further investigation.
The relative advantages and disadvantages of both
techniques should be taken into consideration. However,
TMS and tDCS cannot be directly compared due to the
differences in their mechanisms of action. Both tech-
niques cause different physiological effects, as TMS can
directly elicit action potentials, which is not the case
with tDCS [76,86]. Furthermore, TMS can also affect
areas which are distant, yet functionally connected, to
the stimulated region [87]. Importantly, as a technique,
tDCS is a neuromodulator rather than a method of ex-
trinsic stimulation, and is therefore dependent on the
pre-existing neural state. This may have implications in
the dementias, where intrinsic neural states are poten-
tially different from healthy brains; therefore the transla-
tion of tDCS effects from healthy controls to patient
populations should be done with caution.
A further advantage of TMS is that the manipulation
of timing parameters can result in varied cortical effects
[10-13], which could potentially be used to maximise
treatment efficacy. However, TMS is a more expensive
method than tDCS, needs a degree of technical expertise
to deliver and the magnetic coil is required to be held
still during stimulation, which may be challenging in
cognitively-impaired and often physically frail patient
groups. The use of coil holding rigs and/or robotic arm
systems may help to overcome this issue [88]. Currently,
an advantage of TMS over tDCS is the greater focality of
stimulation [80].
In contrast, there are advantages in the use of tDCS,
as tDCS stimulators are typically inexpensive, battery-
operated and extremely portable. Compared to TMS, tDCS
might also have safety advantages, since no serious adverse
effects have been reported as a result of this technique [19].
Moreover, since the placement of tDCS electrodes follows
the standard International 10–20 system [89], it is feasible
to train non-specialists and/or carers to cheaply administer
tDCS to patients either within a home or clinical environ-
ment. However, as more studies are conducted within
dementia, it is likely that the choice of technique willultimately depend upon the level of efficacy in treating
specific symptoms.
Conclusions
TMS and tDCS may have potential as interventions for
the treatment of symptoms associated with dementia.
However, there are very limited available data in the use
of these approaches in the symptomatic treatment of the
dementias, the majority of trials contained inadequate
control arms, and no data has been reported in sev-
eral major dementia groups (e.g. VaD, PDD, and
FTD). Even in studies with positive outcomes, effect
sizes have been small and the clinical significance of
these remains to be established. Major challenges
exist in terms of appropriate patient selection and
optimisation of the stimulation parameters to obtain
an efficacious response. However, if these issues can
be surmounted, non-invasive stimulation might pro-
vide a novel and alternative therapeutic paradigm for
symptom management in dementia.
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